Significance of interferon-β for the treatment of hepatitis C virus infection in hemodialyzed patients

Hepatology Research

Volumn 40, Issue 9, 2010, Pages 862-869

  Zeniya, Mikio ^a,e   Yokoyama, Keitaro ^b   Imamura, Noritsugu ^c   Murai, Seizo ^d   Ishikawa, Tomohisa ^e   Hokari, Atsushi ^e   Koike, Kazuhiko ^e   Takahashi, Hiroki ^e   Sadaoka, Syunichi ^f  

^a JIKEI University Graduate School of Medicine   (Japan)

^b Center for Hemodialysis   (Japan)

^c Minami Tamachi Clinic   (Japan)

^d Iidabashi Murai Clinic   (Japan)

^e Internal Medicine   (Japan)

^f JIKEI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hemodialysis; Hepatitis C virus; Interferon

Indexed keywords

BETA INTERFERON; PEGINTERFERON ALPHA2A;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEVER; GENOTYPE; HEMODIALYSIS PATIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALAISE; MALE; PRIORITY JOURNAL; PRURITUS; TREATMENT DURATION; VIRUS LOAD;

EID: 77956144144     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2010.00693.x     Document Type: Article

References (31)

1. Fissell BB, Bragg-Gresham JL, Woods JD. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2004, 65:2335-42.
2. Maisonneuve P, Agodoa L, Gellert R. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999, 354:93-9.
3. Nakayama E, Akiba T, Marumo F. Prognosis of anti-hepatitis C virus antibody- positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000, 11:1896-900.
4. Nakai S, Masakane I, Shigemitsu T. Therapeutic Apheresis and dialysis: Official peer-reviewed journal of the international society for apheresis, the Japanese society for apheresis, the Japanese society for dialysis therapy. Ther Apher Dial 2009, 13:457-504.
5. Manns MP, McHutchison JG, Gordon SC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: randomized trial. Lancet 2001, 358:958-65.
6. Fried MW, Shiffman ML, Reddy KR. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-82.
7. Cohen GA, Goffinet JA, Donabedian RK, Conn HO. Observation on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients. Ann Intern Med 1976, 84:275-80.
8. Nanji AA. Decreased activity of commonly measured serum enzyme: cause and clinical significance. Am J Med Technol 1983, 49:241-5.
9. Guh JY, Lai YH, Yang CY. Impact of decreased serum transaminase levels on evaluation of viral hepatitis in hemodialysis patients. Nephron 1995, 69:459-65.
10. Fabrizi F, Lunghi G, Finazzi S. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis 2001, 38:1009-15.
11. Ghany MG, Strader DB, Thomas DL. Diagnosis, management, and treatment of hepatitis C: an updae. Hepatology 2009, 49:1335-73.
12. Pellicano R, Craxi A, Almasio PL. Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005, 11:4484-9.
13. Banwell B, Reder AT, Krupp L. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006, 66:472-6.
14. Desmet VJ, Gerber M, Hoofnagle JH. Classification of chronic hepatitis diagnosis, grading and staging. Hepatology 1994, 19:1513-20.
15. Kawamura Y, Arase Y, Ikeda K. The efficacy of short term interferon-beta therapy for chronic hepatitis C patients with low virus load. Intern Med 2007, 47:355-60.
16. Termorshuizen F, Korevaar JC, Dekker FW, Van Manen JG, Boeschoten EW, Krediet RT. Hemodialysis and peritoneal dialysis:comparisonof adjusted mortality rate according to the duration of dialysis:analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003, 14:2851-60.
17. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease; Guideline 3: preventing HCV transmission in hemodialysis units. Kidney Int 2008, 73(109):S46-52. Preventing HCV Transmission in Hemodialysis Units of KDIGO, Suppl
18. Baid-Agrawal S, Pascual M, Moradpour D, Frei U, Tolkoff-Rubin N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008, 18:97-115.
19. Taltavull C, Baliellas T, Llobet C. Preliminary results of treatment with pegylated interferon alpha 2A for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant Proc 2007, 39:2125-7.
20. Fabrizi F, Dulai G, Dixit V. Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003, 18:1071-81.
21. Russo MW, Goldsweig CD, Jacobson IM. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of literature on efficacy and safety. Am J Gastroenterol 2003, 98:1610-15.
22. Kawamura Y, Arase Y, Ikeda K. The efficacy of short-term Interferon-beta therapy for chronic hepatitis C patients with low virus load. Intern Med 2008, 47:355-60.
23. Arase Y, Suzuki F, Kawamura Y. The efficacy of Interferon-beta monotherapy fot elderly patients with type C hepatitis of genotype 2. Intern Med 2009, 48:1337-42.
24. Zeuzem S, Hultcrantz R, Bourliere M. Peginterferon alpha-2b plus rivabirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol 2004, 40:993-9.
25. 9 Gordon CE, Uhlig K, Lau J. Interferon for hepatitis C virus in hemodialysisi an individual patient meta-analysis of factors associated with sustained virological response. Clin J Am Soc Nephrol 2009, 4:1449-58.
26. Nakajima F, Fukui M, Kitamura T. A case report of Interferon beta monotherapy for hepatitis C viral load in dialysis patients. Ther Apher Dial 2007, 11:306-8.
27. Kuzushita N, Mita E, Nakazuru S. Effect of twice daily intravenous interferon beta booster treatment given for two weeks in patients still HCV-RNA positive at week 24 of Peginterferon alpha-2B plus ribavirin therapy. Hepatology 2008, 48:333.
28. Nakayama H, Shiotani S, Akiyama S. Pharmakokinetic study of human natural beta- interferon in patients with end stage renal failure. Clin Nephrol 2001, 56:382-6.
29. Araoka T, Takeoka H, Nishioka K. Safety and efficacy of Interferon-beta therapy for hemodialysis patient with HCV. Jpn Soc Dial Ther 2009, 42:393-402.
30. Cukor D, Rosenthal DS, Jindai RM, Brown CD, Kimmel PL. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int 2009, 76:679-80.
31. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, manegement, and treatment of Hepatitis C: an update. Hepatology 2009, 49:1335-73.